Anavex Life Sciences Corp (AVXL)

[imho]

Investor,

I used ChatGPT on your post.

1) I asked if the poster is right? ChatGPT said:

The message board poster questions the accuracy of Anavex's statement that their Phase 2b/3 Alzheimer's disease trial met both co-primary endpoints. The trial's co-primary endpoints were cognitive function (measured by ADAS-Cog13) and functional abilities (measured by ADCS-ADL). According to the trial's pre-specified statistical analysis plan, success required both endpoints to achieve a p-value of less than 0.05, or at least one to achieve a p-value of less than 0.025. The reported p-value for ADAS-Cog13 was 0.0226, meeting the criterion. However, the p-value for ADCS-ADL was not reported, and subsequent disclosures indicated that ADCS-ADL did not reach statistical significance. Therefore, the trial did not meet both co-primary endpoints as initially claimed. The poster's conclusion aligns with the available data, suggesting that Anavex's initial statement was inaccurate.

2) I then asked:

"Yea but the company later clarifies:

The trial is successful in meeting the co-primary endpoints if the significance of each endpoint is P < 0.05, or if the significance of only one co-primary endpoint is P < 0.025. If only one primary endpoint is significant at an a level of 0.025, then the secondary endpoint will be evaluated at the same level of 0.025. The trial was successful, since the differences in the least-squares mean (LSM) change from baseline to 48 weeks between the blarcamesine and placebo groups were -1.783 [95% CI, -3.314 to -0.251]; (P = 0.0226) for ADAS-Cog13, and -0.456 [95% CI, -0.831 to -0.080]; (P = 0.0175) for CDR-SB in patients with early Alzheimer’s disease.

ChatGPT said:

In Anavex's Phase 2b/3 Alzheimer's disease trial, the statistical analysis plan outlined specific criteria for determining the success of the co-primary endpoints:

Success Criteria: The trial would be considered successful in meeting the co-primary endpoints if:

Both endpoints achieved a significance level of P < 0.05, or
One endpoint achieved a significance level of P < 0.025.
Secondary Endpoint Evaluation: If only one co-primary endpoint met the P < 0.025 threshold, the secondary endpoint would then be evaluated at the same significance level of P < 0.025.

In the trial results:

The ADAS-Cog13 (a co-primary endpoint) achieved a P-value of 0.0226, which is less than 0.025.

The CDR-SB (secondary endpoint) achieved a P-value of 0.0175, which is also less than 0.025.

Given these outcomes, the trial met its predefined success criteria by demonstrating statistical significance in one co-primary endpoint (ADAS-Cog13) and the secondary endpoint (CDR-SB) at the P < 0.025 level.

Therefore, when the company stated that the trial met "both" its co-primary and key secondary endpoints, it was consistent with the statistical analysis plan's criteria.

IMHO (I am just the messenger - any and all wrath should be targeted at the failings of ChatGPT)